Study of ZD1694 in Advanced Breast Cancer
Author Information
Author(s): I Smith, A Jones, M Spielmann, M Namer, MD Green, J Bonneterre, HE Wander, T Hatschek, N Wilking, J Zalcberg, J Spiers, L Seymour
Primary Institution: Royal Marsden Hospital
Hypothesis
Does ZD1694 provide effective treatment for advanced breast cancer?
Conclusion
ZD1694 shows useful activity in hormone-refractory advanced breast cancer with an overall response rate of 26%.
Supporting Evidence
- 26% of evaluable patients achieved a complete or partial response.
- 44% response rate was observed in patients with liver metastases.
- 85% of patients received their scheduled dose without significant delay.
Takeaway
This study tested a new drug called ZD1694 on women with advanced breast cancer, and it helped some of them feel better.
Methodology
Patients received ZD1694 at a dose of 3.0 mg m-2 as a short infusion every 3 weeks, and their responses were evaluated.
Limitations
The study had a small sample size and was limited to patients with specific prior treatments.
Participant Demographics
The mean age of participants was 58 years, with 98% being Caucasian.
Statistical Information
Confidence Interval
95% CI 14-42%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website